Sienna Biopharmaceuticals, Inc.

Equities

SNNAQ

US82622H1086

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:16:25 2024-05-10 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2021	Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	CI
2021	Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.	CI

Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.

February 04, 2021

Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million on January 29, 2021. Frederick (Erik) Schmidt of Cozen O'Connor acted as legal advisor for Sienna and Mike Gustafson of Faegre Drinker Biddle & Reath LLP acted as legal advisor for Avro Life Sciences, Inc.

Latest news about Sienna Biopharmaceuticals, Inc.

Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	21-02-05	CI
Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.	21-02-04	CI
Sebacia, Inc. completed the acquisition of all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q).	20-01-08	CI
Motion For Case Conversion Approved for Sienna Biopharmaceuticals, Inc.	19-12-18	CI
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from NASDAQ Composite Index	19-12-16	CI
Motion for Case Conversion Filed by Sienna Biopharmaceuticals, Inc.	19-12-12	CI
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	19-12-09	CI
Sebacia, Inc. entered into a sale purchase agreement to acquire all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $1.7 million.	19-12-09	CI
Notice of Selection of Successful Bidder Filed by Sienna Biopharmaceuticals, Inc.	19-12-04	CI
Bidding Procedure Approved for Sienna Biopharmaceuticals, Inc.	19-11-12	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Motion for Asset Sale Filed by Sienna Biopharmaceuticals, Inc.	19-10-22	CI
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair	19-10-07	CI
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P Global BMI Index	19-09-19	CI
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P TMI Index	19-09-19	CI
Sienna Biopharmaceuticals, Inc. Filed for Bankruptcy	19-09-16	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI
Sienna To Explore Strategic Alternatives	19-08-05	CI
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from Russell 2000 Dynamic Index	19-06-28	CI
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%)	19-06-10	CI
Transcript : Sienna Biopharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 03:55 PM	19-05-15
Sienna Biopharmaceuticals, Inc. Announces SNA-120 Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines	19-05-14	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-08	CI
Certain Common Stock of Sienna Biopharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2019.	19-04-21	CI
Certain Stock Options of Sienna Biopharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2019.	19-04-21	CI

Chart Sienna Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The Company's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SIENNA BIOPHARMACEUTICALS, INC.	0.00%	22
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs